Dainippon Sumitomo Pharma to Release AmBisome 50mg, Antifungal Agent for Deep-seated Mycosis Infection.Tokyo, Japan, June 16, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Dainippon Sumitomo Pharma will release AmBisome 50mg for intravenous drip infusion, an antifungal agent for treating deep-seated mycosis mycosis: see fungal infection. infection, on June 20. AmBiosome, which the company has licensed from US company Gilead Sciences, is a liposomal formulation of amphotericin B. It retains the efficacy of amphotericin B while reducing the damage to kidneys. AmBisome is the only antifungal agent indicated for the treatment of febrile febrile /feb·rile/ (feb´ril) pertaining to or characterized by fever. feb·rile adj. Of, relating to, or characterized by fever; feverish. neutropenia with suspected mycotic mycotic /my·cot·ic/ (mi-kot´ik) 1. pertaining to mycosis. 2. caused by a fungus. my·cot·ic adj. 1. Relating to mycosis. 2. infection. The agent is currently available in 45 countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion